JPM hit different this year.
San Francisco delivered its signature steep hills, mystical fog and light rain, so that wasn’t the difference. Lines into parties wrapped down stairways and into narrow alleys, just like years past. As I rushed around bumping into old friends, there was an undeniable energy, a resilient spirit that was tangible. I sensed our commitment to advancing healthcare re-emerging from the headwinds our industry faced in 2023.
The 42nd J.P. Morgan Healthcare Conference was a space for unity ... and dare I say hope? My professional friends and colleagues, each having navigated tough decisions this year, gathered with a sense of shared experience. Tired smiles and nods were exchanged, and eye contact spoke volumes. Our collective sighs created an unspoken language among us. Yet, this community had gathered to envision the possibilities of what’s to come.
Our work goes beyond market fluctuations; it is driven by a deeper purpose. This year’s meeting alluded to the past year but didn’t dwell there. Presentations and discussions showcased hot topics such as NVIDIA’s point of view on generative AI in healthcare as well as major collaborations such as Microsoft and Mayo Clinic backing the Coalition for Health AI. Attendees parted with a firm belief in the transformative power of our industry.
One of my most inspiring moments at JPM was reconnecting with a former client and founder of a company that really speaks to this transformative power. Dena Marrinucci, founder and chief operating officer of Truvian, embodies an unwavering commitment to a greater purpose — the betterment of healthcare for all through a commitment to diligence and transparency. We met up this year at a party thrown by Illumina Ventures, Amazon Web Services, Silicon Valley Bank and Cooley LLP. After sharing a few laughs, she extended a very special invitation. Would I like to join her the next day in Truvian’s suite to have my blood drawn and analyzed on their benchtop instrument? Would I ever!
The next day, I entered the suite, completed my consent paperwork and had a small tube of blood drawn. I walked to the Truvian instrument, which sat on a simple bench in front of a window overlooking the San Francisco skyline. I then entered my information, placed my blood sample in the instrument and touched the screen to start the test. I barely had enough time to download the Truvian app to my phone and input my test number before I had the test results in the palm of my hand. I was in and out of the suite, with my results, in about 30 minutes.
By leveraging three commonly used testing technologies — immunoassay, clinical chemistry and hematology — the platform runs, simultaneously, the most ordered tests that account for greater than 90% of blood test orders. Throughout the platform’s journey, Truvian committed to consulting with the industry’s top advisors to ensure it would accurately break through the blood testing industry — unlike previous attempts by others attempting a similar feat. And here’s the thing — I recently had a routine series of blood tests ordered by my doctor. The results matched Truvian’s! The instrument is designed to show the interworking of its technology in real time. Seeing those results firsthand was nothing short of awe-inducing. Now take a moment to imagine the impact of having one of these instruments in every doctor’s office and retail pharmacy — especially on historically marginalized communities. This type of technology could reintroduce a trust and transparency in healthcare that we once thought was gone.
My interaction with Truvian serves as an important reminder that our industry is not just about business; it's about the lives we impact, the patients we serve and the collective hope we instill in the face of challenges. As I think back on JPM, I see a renewed sense of purpose and a belief that we will not only thrive again but continue to drive transformative change.